Form 8-K - Current report:
SEC Accession No. 0001193125-24-266101
Filing Date
2024-11-26
Accepted
2024-11-26 16:05:53
Documents
13
Period of Report
2024-11-22
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d848587d8k.htm   iXBRL 8-K 22891
  Complete submission text file 0001193125-24-266101.txt   140117

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA lyel-20241122.xsd EX-101.SCH 2845
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE lyel-20241122_lab.xml EX-101.LAB 17236
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE lyel-20241122_pre.xml EX-101.PRE 10809
15 EXTRACTED XBRL INSTANCE DOCUMENT d848587d8k_htm.xml XML 3508
Mailing Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SOUTH SAN FRANCISCO CA 94080 650 695-0677
Lyell Immunopharma, Inc. (Filer) CIK: 0001806952 (see all company filings)

EIN.: 833006753 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40502 | Film No.: 241503675
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)